Last reviewed · How we verify
ND0611
At a glance
| Generic name | ND0611 |
|---|---|
| Sponsor | NeuroDerm Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Safety, Tolerability and Pharmacokinetic Study of ND0611 on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Parkinson's Disease Patients (PHASE1, PHASE2)
- Safety, Tolerability and Pharmacokinetic Profile of Levodopa Administered With Continuous Administration of ND0611 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ND0611 CI brief — competitive landscape report
- ND0611 updates RSS · CI watch RSS
- NeuroDerm Ltd. portfolio CI